一项主要研究发现Natera的信号测试通过及时指导化疗,改善了结肠癌患者在第二阶段的存活率。 A major study finds Natera’s Signatera test improves survival in stage II colon cancer patients by guiding timely chemotherapy.

在一份经同行审查的期刊上发表的具有里程碑意义的第三阶段试验显示,利用Natera的Signatera液体活性检查检测,在手术后发现最起码的残余疾病,使第二阶段结肠癌患者的复发性得以改善。 A landmark Phase III trial published in a peer-reviewed journal shows that using Natera’s Signatera liquid biopsy test to detect minimal residual disease after surgery improved recurrence-free survival in stage II colon cancer patients. 该研究涉及多个美国医疗中心,发现在Signatera结果指导下作出的治疗决定导致及早发现高风险病人,从而能够及时进行临时化疗。 The study, involving multiple U.S. medical centers, found that treatment decisions guided by Signatera results led to earlier detection of high-risk patients, enabling timely adjuvant chemotherapy. 这支持使用无细胞DNA检测,使护理个性化,并提高早期结肠癌的结果。 This supports the use of cell-free DNA testing to personalize care and enhance outcomes in early-stage colon cancer.